Linezolid treatment of vancomycin-resistant Enterococcus faecium ventriculitis.
The successful treatment of a 7-month-old infant with shunt-associated ventriculitis caused by vancomycin-resistant Enterococcus faecium is presented. Linezolid was administered intravenously every 8 h; children have a greater volume of distribution and total body clearance than adults and therefore require more frequent dosing. The patient tolerated the therapy without adverse effects.
Graham
Philip L
PL
Departments of Pediatrics and Epidemiology, Columbia, University, New York, NY 10032, USA. pgl43@columbia.edu
Ampofo
Krow
K
Saiman
Lisa
L
D000081:Acetamides / Q000627:therapeutic use*; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D004660:Encephalitis / Q000188:drug therapy* / Q000382:microbiology*; D016984:Enterococcus faecium / Q000302:isolation & purification*; D016908:Gram-Positive Bacterial Infections / Q000188:drug therapy* / Q000382:microbiology*; D006801:Humans; D006849:Hydrocephalus / Q000188:drug therapy / Q000382:microbiology; D007223:Infant; D000069349:Linezolid; D008297:Male; D023303:Oxazolidinones / Q000627:therapeutic use*; D020713:Vancomycin Resistance; D017287:Ventriculoperitoneal Shunt / Q000009:adverse effects
D000081:Acetamides; D000900:Anti-Bacterial Agents; D023303:Oxazolidinones; D000069349:Linezolid